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Original Article
Consultation rates in cervical screening
non-attenders: opportunities to increase
screening uptake in GP primary care
Anita Wey Wey Lim and Peter Sasieni
Abstract
Objective: To estimate the proportion of cervical screening non-attenders presenting to general practice (GP) primary care
over one year.
Setting: 137 practices in East London, UK.
Methods: Anonymous primary care records were downloaded using EMIS web (clinical software). Cervical screening non-
attendance was defined as no recorded smear in the last 3.5 years (women aged 25–49) or 5.5 years (women aged 50–64). The
last three consultation entries were used to estimate the proportion of non-attenders who consulted in GP over 3 months and
1 year using the Kaplan-Meier method. Newly registered women were assessed separately. Results were calculated for each
practice and the median and interquartile range (IQR) across practices are presented. Heterogeneity was assessed using funnel
plots.
Results: Of 261,810 women, 224,313 (86%) had been registered for >1 year. The proportion classified as non-attenders
differed between those registered for >1 year (30%, IQR 27%–35%) and within the last year (49%, IQR 40%–57%), suggesting
that screening records were less up-to-date in newly registered women. A median of 32% (IQR: 27%–37%) of non-attenders
presented over 3 months, and 60% (IQR: 52%–67%) over 1 year. Funnel plots of the proportion of non-attenders presenting by
the number of non-attenders showed substantial variation between practices.
Conclusions: Over half of cervical screening non-attenders present to their GP at least once a year, in over 75% of practices.
This represents a good opportunity for improving coverage by offering an alternative form of screening, such as self-sampling for
human papillomavirus testing.
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Introduction
In England, cervical cancer screening is estimated to save
up to 4,500 lives annually.1 Nevertheless, 2,482 women
were diagnosed2 and 742 died from the disease in 2012.3
Nonattendance for screening is one of the most important
risk factors for developing cervical cancer,4 but screening
coverage (the proportion of eligible women who are regu-
larly screened) has been falling since the mid 1990s.5
Screening uptake is particularly low in young women (aged
25–29),6 women who live in deprived areas, and women
from ethnic minorities.7–9 There is a well-recognized need
to develop strategies to increase screening uptake in these
women, who are at high risk of developing cervical cancer.
The most commonly cited barriers to cervical screening
relate to the pelvic examination (eg. embarrassment, fear
of pain) and to practical issues (eg. making appointments,
arranging childcare, getting time oﬀ work).10–12 Self-
sampling for high-risk human papillomavirus (HPV)
types has the potential to overcome these; women can
take their own test in private, at a time and place of
their choosing. Several studies13–19 have assessed the
uptake of self-sampling for HPV testing in screening
non-attenders. Approaches have included posting self-
sampling kits directly to women10,13,15,19–23 writing to
women to ask them to order kits,15–17 and oﬀering kits
door-to-door.14 Response rates have ranged between
8.7% and 52.1%, and were highest in women who were
oﬀered kits in person (ie. door-to-door). Studies which
posted self-sampling kits achieved response rates of
around 30% in Northern Europe,13,16,17,19–23 but only
Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine,
Queen Mary University of London, Charterhouse Square, London EC1M
6BQ
Corresponding author:
Dr Anita Wey Wey Lim, Queen Mary University of London, Centre for
Cancer Prevention, Wolfson Institute of Preventive Medicine, Charterhouse
Square London, EC1M 6BQ United Kingdom.
Email: a.lim@qmul.ac.uk
J Med Screen
2015, Vol. 22(2) 93–99
! The Author(s) 2015
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0969141315573345
msc.sagepub.com
6–8% of women returned a self-sample in two UK
studies.10,24
One approach that has not been assessed is oﬀering
self-sampling for HPV testing opportunistically to cervical
screening non-attenders in primary care. Women would
be oﬀered a self-sampling kit when they present to their
GP for any reason. This takes advantage of the fact that
the woman is already in clinic (allowing an in person
approach), and kits do not need to be ordered or sent
(fewer wasted kits and easier for women). The success of
this approach depends on a reasonable proportion of
screening non-attenders presenting to their GP.
Currently little is known about cervical screening non-
attenders’ consulting behaviour. The aim of this audit
was to estimate the proportion of cervical screening
non-attenders that present to their GP and the frequency
of attendance over one year, using anonymous electronic
primary care records.
Methods
Data collection
Anonymous data on women within the cervical screening
age range (ie. 25–64) were downloaded from GP computer
databases on 31 December 2012 using EMIS Web (Egton
Medical Information Systems Ltd, 2010 – one of the main
software suppliers to UK GPs). We collected data from all
137 general practices in three primary care trusts (PCTs,
now known as CCGs – Clinical Commissioning Groups)
in East London (Newham, City and Hackney, and Tower
Hamlets) that use EMIS web. Eight further practices were
excluded because they used other electronic patient record
software. Data included age, date of registration at the
practice, details of the last three consultation entries, cer-
vical screening records (dates and codes for the most
recent smear entry and for withdrawal or cease from the
screening programme), and aggregated ethnicity data for
each practice.
Analysis
In England, women aged 25–49 are invited to cervical
screening every 3 years, and women aged 50–64 are invited
every 5 years. We therefore classiﬁed women’s cervical
screening status as follows:
1. ‘Up to date’ – women whose last smear was recorded
within 3 years (women aged 25–49) or 5 years (women
aged 50–64) prior to download date.
2. ‘Due’ – women whose last smear was recorded
>3 and 43.5 years (women aged 25–49) or >5 and
45.5 years (women aged 50–64) prior to download
date.
3. ‘Late’ – women whose last smear was recorded >3.5
and 45.5 years (women aged 25–49) or >5.5 and
47.5 years (women aged 50–64) prior to download
date.
4. ‘Very late’ – women whose last smear was >5.5 years
(women aged 25–49) or >7.5 years (women aged 50–
64) prior to download date.
5. ‘Never’ – women with no smear recorded and who
were not classiﬁed as ‘ceased’ (ie. still has cervix, see
6) below)
6. ‘Ceased’ – women who were withdrawn from cervical
screening because their cervix had been removed or
amputated (eg. hysterectomy) or who had the clinical
code ‘‘8I6K – cervical smear not indicated’’ (eg. for
women who are terminally ill).
7. ‘Unknown’ – women who had been previously
screened but for whom the date was missing from
their most recent smear entry.
Women withdrawn from screening by informed choice (ie.
had clinical code entries for cervical screening disclaimer
forms) were also classiﬁed by the above criteria because
these women may agree to take a self-sample (eg. if opting
out was due to dislike of the pelvic examination).
‘Screening non-attenders’ were deﬁned as women who
were more than six months overdue screening (‘late’, ‘very
late’) or never screened (‘never’).
When patients move practice there can be delays in
transferring their medical records. This could have poten-
tially led to misclassiﬁcations in screening status.
Therefore, we compared screening status for women
who were newly registered within a year of data download
with those who had been registered for over one year.
Consultation entries in EMIS include non-consulta-
tions such as outpatient letters, laboratory test results,
and administration notes. This meant that only limited
consultation data were available for women who had
non-visit entries for all three. To make best use of the
available data we used the Kaplan-Meier method (ie. cen-
soring those who had three non-visit entries at the time of
the earliest entry) to estimate the proportion of women
who presented over three months and over one year as a
function of time, for each practice. Median (and inter-
quartile range [IQR]) of these estimates were then calcu-
lated for screening non-attenders (the main group of
interest). We also calculated these for all women, and
for three other groups of interest:
1. Prompt attenders – screening categories ‘up to date’
and ‘due’
2. Lapsed attenders (ie previously screened and >6
months overdue) – screening categories ‘late’ or ‘very
late’
3. Never attenders – screening category ‘never’.
We used funnel plots to explore whether diﬀerences
between practices in the proportion of screening non-
attenders presenting were random or were more likely to
be due to other factors (eg. ethnicity, age). To explore
heterogeneity in our estimates between practices, we
used linear regression to assess whether the proportion
of screening non-attenders consulting over 3 months at
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each practice was aﬀected by the number of women aged
25–64 registered for >1 year, or the proportion of non-
attenders registered for >1 year.
We calculated the median and IQR time in years from
last cytology test to date of download for screening non-
attenders within screening age bands 25–49 and 50–64. All
statistical analyses were performed using Stata Statistical
Software: Release 12. StataCorp. 2011 (College Station,
TX: StataCorp LP). A p value of less than 0.05 was con-
sidered statistically signiﬁcant. All statistical tests were
two-sided.
Results
A total of 261,810 women aged 25–64 were included in the
audit. Table 1 shows the practice details for all practices
combined and by PCT. Although Tower Hamlets had
larger practices, there were fewer women in the cervical
screening age range. All three PCTs had ethnically diverse
populations; over a third of patients were South Asian at
Tower Hamlets and Newham. Overall, 86% (224,313) of
women had been registered for at least one year.
Table 2 shows how screening status varied according to
whether or not women were newly registered within the
previous year. More newly registered women were classi-
ﬁed as ‘never’ screened, (median 43% [IQR 35%–53%]
versus 15% [IQR 13%–19%]), and fewer were ‘up to
date’ (median 49% [IQR 41%–56%] versus 63% [IQR
58%–66%]). Of those ever screened, however, a higher
proportion of newly registered women (median 89%
[IQR 84%–92%]) than other women (median 77% [IQR
74%–80%]) were ‘up to date’ with screening.
Table 1. General Practice details by primary care trust.
Tower Hamlets (n¼ 36) Newham (n¼ 61) City and Hackney (n¼ 40) Total (n¼ 137)
List size
Median (IQR) 7388 (4395, 10445) 4970 (3191, 8606) 5772 (4440, 9058) 5925 (3944, 9569)
Range 1563–17980 1399–15791 879–13389 879–17980
Number registered >1 year 68,180 (84%) 84,290 (87%) 71,843 (86%) 224,313 (86%)
Ethnicity
White 38% 26% 47% –
Black 7% 19% 22% –
South Asian 37% 42% 7% –
Other 6% 4% 9% –
Not recorded 11% 9% 15
Age in years
25 6% 4% 4% 11,898 (5%)
26–27 11% 9% 9% 25,401 (10%)
28–37 46% 38% 40% 107,360 (41%)
38–49 22% 28% 28% 67,697 (26%)
50–64 15% 21% 20% 49,454 (19%)
Number of women aged 25–64 years 81,528 96,973 83,309 261,810
IQR¼interquartile range.
Table 2. Screening status (median and interquartile range) for women registered 41 year and >1 year and for all women.
Screening status
Women registered
for 41 year Median %
(IQR) N¼ 37,497
Women registered
for >1 year Median %
(IQR) N¼ 224,313
All women
Median % (IQR)
N¼ 261,810
Up to date 49% (41%–56%) 63% (58%–66%) 60% (56%–65%)
Due 1% (0.3%–2%) 4% (3%–5%) 4% (3%–4%)
Late 3% (2%–4%) 9% (7%–10%) 8% (7%–9%)
Very late 2% (1%–3%) 6% (4%–8%) 6% (4%–7%)
Never 43% (35%–53%) 15% (13%–19%) 19% (16%–23%)
Ceased 1% (0.4%–2%) 3% (2%–4%) 2% (2%–4%)
Screening non-attenders (late/very late/never) 49% (40%–57%) 30% (27%–35%) 33% (29%–37%)
IQR¼ interquartile range.
Note: Additionally, 68 women (0.026%) had unknown screening status.
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Table 3 shows the median and IQR of Kaplan-Meier
estimates across practices for the proportion of women
who consulted over three months and over one year for
all women, and according to screening history. A median
of 32% (IQR 27%–37%) of screening non-attenders con-
sulted at least once over three months, and 60% (IQR
52%–67%) over one year. In three-quarters of practices
at least 37% of screening non-attenders consulted over
three months and at least 67% over 12 months. The
median proportion of women that consulted was lowest
in never attenders (never screened) for both time periods.
Only 9% (5991/68,715) of screening non-attenders were
censored because there were insuﬃcient data to determine
if they had consulted in the past 12 months (ie. all three
consultation entries within 12 months were non-visit
entries). For screening non-attenders aged 25–49, the
median time since last smear was ﬁve years (IQR 4–7)
and for those aged 50–64 this was nine years (IQR 7–
13). Figure 1a and b both show a roughly symmetrical
funnel shaped distribution for the proportion of screening
non-attenders that consulted over each time period by the
number of women in the cervical screening age at each
practice. However, approximately two thirds were scat-
tered outside of the 99.8% control limits (dotted lines)
for both periods, indicating substantial heterogeneity
between the practices and hence the need to report
median and IQR in Tables 2 and 3.
We also looked at practice-speciﬁc factors that might
predict the proportion of screening non-attenders present-
ing over three months. The proportion of screening non-
attenders presenting was unaﬀected by the number of
women aged 25–64 at each practice registered >1 year
(p¼0.448) and by the proportion of screening non-atten-
ders registered >1 year (p¼0.238).
Discussion
Main findings
Over half of cervical screening non-attenders in East
London present to their GP at least once a year, and
approximately a third over three months. This suggests
that a reasonable proportion of screening non-attenders
could be oﬀered opportunistic self-sampling for HPV test-
ing when they present to their GP. The proportion varied
substantially between practices.
Cervical screening data in GP medical records appears
to be unreliable within a year of registration, as the pro-
portion of women who were classiﬁed as ‘never’ screened
was much higher in comparison with women registered for
more than a year. The fact that a higher proportion of
newly registered women who had been screened previ-
ously were ‘up to date’ could indicate that registration
visits are being used as an opportunity to carry out or
remind women about cervical screening. Cervical screen-
ing non-attenders consult their GP less often (60% within
one year) than do screening attenders (86% within one
year), but it is not the case that non-attenders do not
engage with the National Health Service.
Strengths and weaknesses
A key strength of this study is the large and unbiased
database. Excluding women who were newly registered
in the last year in the main analysis allowed us to calculate
more accurate estimates within screening categories.
Because we only had partial consultation data, the pro-
portion of women who presented is likely to have been
under- or over-estimated. However, the use of Kaplan-
Meier ensured that all available information was used
for our estimates. Only 9% of screening non-attenders
were censored (because they had non-consultation entries
for all available entries), suggesting that any under- or
over-estimation was small. Because our audit was limited
to practices in a single urban area of London with a high
proportion of South Asians, our data may not be repre-
sentative of the rest of England. It is known that a high
proportion of South Asians are cervical screening non-
attenders,8 but we were not able to study consulting
behaviour separately in South Asians and White screening
non-attenders.
Comparison with other studies
We are not aware of any studies that have speciﬁcally
examined GP primary care consultation rates in cervical
screening non-attenders. However, a questionnaire study
in Denmark found that GP consultation rates were lower
in non-attenders who had never been screened than those
Table 3. Median (interquartile range) Kaplan-Meier estimates of
the proportion of women aged 25–64 consulting over 3 months and
1 year for women registered for >1 year for all women and by
screening attendance.
Median (IQR) proportion of women who consulted in the past
3 months
All women 48% (44%–52%)
By screening attendance
Prompt attender 56% (51%–60%)
Lapsed attender 37% (29%–43%)
Never attender 28% (22%–33%)
Screening non-attenders (late/very late/never) 32% (27%–37%)
Median (IQR) proportion of women who consulted in the past 1
year
All women 77% (73%–82%)
By screening attendance
Prompt attender 86% (83%–89%)
Lapsed attender 62% (55%–73%)
Never attender 57% (48%–64%)
Screening non-attenders (late/very late/never) 60% (52%–67%)
IQR¼interquartile range.
Prompt attender¼screening categories ‘up to date’ and ‘due’.
Lapsed attender¼ screening categories ‘late’ and ‘very late’.
Never attender¼ screening category ‘never’.
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who had attended screening at least once (64% of never
attenders consulted over one year compared with 83% of
ever attenders, p< 0.0001).25
Implications
A substantial proportion of cervical screening non-atten-
ders could potentially be oﬀered self-sampling for HPV
testing when they present to their GP. This has the poten-
tial to increase screening coverage. Studies have shown
that a high proportion (often >80%) of women who test
HPV positive on a self-sample attend for follow up inves-
tigations (eg. cytology or colposcopy).23,26,27 For oppor-
tunistic self-sampling to work, not only do screening
non-attenders need to attend their GP, but the health pro-
fessional consulted needs to invite the women to take a
self-sample. This may not always be possible due to time
constraints (the average GP consultation lasts around 12
minutes28) or illness.
Based on these results we are further investigating the
potential for opportunistic oﬀering of self-sampling for
HPV testing in pilot study (to assess feasibility and accept-
ability). This will be followed by a large randomized con-
trolled trial.
Conclusion
Over one year, over half of cervical screening non-atten-
ders could be oﬀered self-sampling for HPV testing oppor-
tunistically when they present to their GP. This approach
should be explored further as a means to increase cervical
screening coverage.
Figure 1. Funnel plots showing the proportion of screening non-attenders presenting by the number within the cervical screening age at
each practice (for women registered >1 year).
Control limits indicated by the dashed lines are set at 95% and 99.8%.
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